N. Colombo

发表

Early Detection of Anthracycline Cardiotoxicity and Improvement With Heart Failure Therapy

G. Curigliano, F. Veglia, C. Cipolla, 2015, Circulation.

ICON2: randomised trial of single-agent carboplatin against three-drug combination of CAP (cyclophosphamide, doxorubicin, and cisplatin) in women with ovarian cancer

M. Buyse, E. Dreher, Torri, 1998, The Lancet.

Randomized phase III trial of bleomycin, vindesine, mitomycin-C, and cisplatin (BEMP) versus cisplatin (P) in disseminated squamous-cell carcinoma of the uterine cervix: an EORTC Gynecological Cancer Cooperative Group study.

J. Vermorken, I. Teodorović, N. Colombo, 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

Prevention of Atrial Fibrillation in High-risk Patients Undergoing Lung Cancer Surgery: The PRESAGE Trial

M. Casiraghi, M. Venturino, L. Spaggiari, 2016, Annals of surgery.

Sentinel lymph node biopsy in pregnant patients with breast cancer

Umberto Veronesi, Paolo Veronesi, Giovanni Paganelli, 2009, European Journal of Nuclear Medicine and Molecular Imaging.

Response to Letters Regarding Article, "Early Detection of Anthracycline Cardiotoxicity and Improvement With Heart Failure Therapy".

G. Curigliano, F. Veglia, C. Cipolla, 2016, Circulation.

Acute coronary syndrome induced by oral capecitabine.

A. Colombo, D. Cardinale, N. Colombo, 2006, The Canadian journal of cardiology.

A reassessment of the role of second-look laparotomy in advanced ovarian cancer.

N. Colombo, U. Beller, N. Colombo, 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase II, randomized trial of neo-adjuvant chemotherapy comparing a three-drug combination of paclitaxel, ifosfamide, and cisplatin (TIP) versus paclitaxel and cisplatin (TP) followed by radical surgery in patients with locally advanced squamous cell cervical carcinoma: the Snap-02 Italian Collabo

V. Torri, D. Katsaros, F. Landoni, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

Consolidation with intraperitoneal cisplatin in first-line therapy of advanced ovarian cancer.

A. Zeleniuch‐Jacquotte, H. Hochster, U. Beller, 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effectiveness and safety of posatirelin in the treatment of senile dementia: A multicenter, double-blind, placebo-controlled study

D. Cucinotta, N. Colombo, R. Girardello, 1998 .

QTc prolongation assessment in anticancer drug development: clinical and methodological issues

A. Goldhirsch, F. D. De Braud, G. Curigliano, 2009, Ecancermedicalscience.

Response to Letter Regarding Article, “Prevention of High-Dose Chemotherapy–Induced Cardiotoxicity in High-Risk Patients by Angiotensin-Converting Enzyme Inhibition”

F. Veglia, G. Martinelli, C. Cipolla, 2007 .

Clinical Relevance and Response to Pharmacologic Therapy

F. Veglia, C. Cipolla, C. Fiorentini, 2010 .

Total intravenous anesthesia with propofol in pediatric patients for MR examination.

G. Scialfa, G. Savoia, L. Monsein, 1994, AJNR. American journal of neuroradiology.

Intraperitoneal recombinant interferon gamma in ovarian cancer patients with residual disease at second-look laparotomy.

A. Monnier, P. Fumoleau, E. Pujade-Lauraine, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Early predictors of peripheral neurotoxicity in cisplatin and paclitaxel combination chemotherapy.

A. Lissoni, G. Cavaletti, N. Colombo, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

Intraperitoneal carboplatin: favorable results in women with minimal residual ovarian cancer after cisplatin therapy.

N. Colombo, H. Hochster, F. Muggia, 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Rosia: A Single-Arm Study in More Than 1000 Patients (PTS) Receiving Front-Line Bevacizumab (BEV) + Chemotherapy (CT) for Ovarian Cancer (OC)

A. Oza, N. Colombo, F. Selle, 2012 .

Advanced ovarian cancer. Dose intensity.

M. Piccart, R. Ozols, J. Thigpen, 1993, Annals of oncology : official journal of the European Society for Medical Oncology.

Prognostic Value of Troponin I in Cardiac Risk Stratification of Cancer Patients Undergoing High-Dose Chemotherapy

G. Martinelli, C. Cipolla, F. Peccatori, 2004, Circulation.

Reply to S. Goel et al and P.A. Kavsak et al

F. Veglia, C. Cipolla, A. Colombo, 2011 .

Long QT syndrome and torsade de pointes after anthracycline chemotherapy

A. Colombo, D. Cardinale, M. Civelli, 2009, Ecancermedicalscience.

Risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes: ESMO Clinical Practice Guideline.

J. Ledermann, S. Loibl, B. Lemley, 2022, Annals of oncology : official journal of the European Society for Medical Oncology.

Chemotherapy in advanced ovarian cancer: an overview of randomised clinical trials. Advanced Ovarian Cancer Trialists Group.

D. Alberts, M. Buyse, L. Stewart, 1991, BMJ.

Follow-up study of enzymuria and β2 microglobulinuria during cis-platinum treatment

B. Assael, C. Mangioni, N. Colombo, 2004, European Journal of Clinical Pharmacology.

Selection of cancer chemotherapy for a patient by an in vitro assay versus a clinician.

M. Piccart, D. V. Von Hoff, G. Clark, 1990, Journal of the National Cancer Institute.

Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trials. Advanced Ovarian Cancer Trialists' Group.

D. Alberts, W. Sauerbrei, M. Buyse, 1998, British Journal of Cancer.

Iron‐ovotransferrin preparation does not interfere with ciprofloxacin absorption

C. Sirtori, D. Baldassarre, N. Colombo, 1996, Clinical pharmacology and therapeutics.

Prevention of High-Dose Chemotherapy-Induced Cardiotoxicity in High-Risk Patients by Angiotensin-Converting Enzyme Inhibition

Giovanni Martinelli, Fabrizio Veglia, Carlo M. Cipolla, 2006, Circulation.

234O Maintenance olaparib for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): 5-year (y) follow-up (f/u) from SOLO1

M. Friedlander, C. Aghajanian, A. Leary, 2020, Annals of Oncology.

Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy.

F. Veglia, C. Cipolla, C. Fiorentini, 2010, Journal of the American College of Cardiology.

A phase II trial of the mTOR inhibitor AP23573 as a single agent in advanced endometrial cancer

D. Matei, M. Einstein, C. Sessa, 2007 .

Phase II of oral gimatecan in patients with recurrent epithelial ovarian, fallopian tube or peritoneal cancer, previously treated with platinum and taxanes

D. Katsaros, A. Lissoni, I. Ray-Coquard, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

813MO Efficacy of subsequent chemotherapy for patients with BRCA1/2 mutated platinum-sensitive recurrent epithelial ovarian cancer (EOC) progressing on olaparib vs placebo: The SOLO2/ENGOT Ov-21 trial

A. Oza, J. Ledermann, T. Park-Simon, 2020 .

Propofol anaesthesia in spontaneously breathing paediatric patients during magnetic resonance imaging

G. Scialfa, G. Savoia, C. Tommasino, 1996, Acta anaesthesiologica Scandinavica.

Pericardial-peritoneal window for malignant pericardial effusion

D. Radice, F. Petrella, L. Spaggiari, 2018 .

721O Relacorilant, a selective glucocorticoid receptor modulator, in combination with nab-paclitaxel improves progression-free survival in patients with recurrent platinum-resistant ovarian cancer: A 3-arm, randomized, open-label, phase II study

G. Fleming, T. Van Gorp, A. Oaknin, 2021, Annals of Oncology.

Platinum versus platinum-combination chemotherapy in platinum-sensitive recurrent ovarian cancer: a meta-analysis using individual patient data.

D. Alberts, M. Parmar, V. Torri, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Antiemetic activity of two different high doses of metoclopramide in cisplatin-treated cancer patients: a randomized double-blind trial of the Italian Oncology Group for Clinical Research.

M. Tonato, F. Roila, R. Passalacqua, 1985, Cancer treatment reports.

Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation.

F. Veglia, C. Cipolla, A. Colombo, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adjuvant treatment for early epithelial ovarian cancer: Results of two randomised clinical trials comparing cisplatin to no further treatment or chromic phosphate (32P)

V. Torri, S. Marsoni, N. Colombo, 1995 .

Cardio-oncology: a new medical issue

N. Colombo, A. Colombo, D. Cardinale, 2008, Ecancermedicalscience.

Dosimetric study to assess the feasibility of intraoperative radiotherapy with electrons (ELIOT) as partial breast irradiation for patients with cardiac implantable electronic device (CIED)

M. Winnicki, G. Corso, M. Leonardi, 2018, Breast Cancer Research and Treatment.

Cardioncological Approach for Trastuzumab Therapy in Breast Cancer Patients With Cardiotoxicity: Impact on Adherence and Clinical Outcome

C. Cipolla, D. Cardinale, N. Colombo, 2020, Frontiers in Pharmacology.

Radiotherapy in patients with cardiac implantable electronic devices: clinical and dosimetric aspects

R. Orecchia, C. Cipolla, C. Garibaldi, 2018, Medical Oncology.

Primary cardiac lymphoma with isolated parenchymal central nervous system relapse: report of two cases and review of the literature

G. Martinelli, L. Preda, M. Civelli, 2014, Ecancermedicalscience.

Using t he E xpected S urvival t o E xplain D ifferences Between t he R esults o f R andomized T rials: A C ase i n A dvanced O varian C ancer

M. Buyse, M. Parmar, V. Torri, 2003 .

Increased Perioperative N-Terminal Pro-B-Type Natriuretic Peptide Levels Predict Atrial Fibrillation After Thoracic Surgery for Lung Cancer

G. Veronesi, L. Spaggiari, F. Veglia, 2007, Circulation.

812MO Maintenance olaparib + bevacizumab (bev) in patients (pts) with newly diagnosed advanced high-grade ovarian cancer (HGOC): RECIST and/or CA-125 objective response rate (ORR) in the phase III PAOLA-1 trial

P. Sevelda, I. Ray-Coquard, G. Scambia, 2020 .

Early reduction in left ventricular contractile reserve detected by dobutamine stress echo predicts high-dose chemotherapy-induced cardiac toxicity.

G. Martinelli, C. Cipolla, S. Gandini, 2006, International journal of cardiology.

Neoadjuvant chemotherapy with cisplatin, ifosfamide and paclitaxel for locally advanced squamous-cell cervical cancer.

A. Lissoni, C. Sessa, N. Colombo, 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

Randomised trial comparing doxorubicin, paclitaxel (AT), versus paclitaxel (T), as second line therapy for advanced ovarian cancer (AOC) patients in early progression after platinum-based chemotherapy.

Torri, I. Floriani, P. Conte, 2000 .

Phase II study comparing volociximab (an antiangiogenic antibody) and pegylated liposomal doxorubicin (PLD) with PLD alone in recurrent ovarian or primary peritoneal cancer.

E. Lengyel, I. Vergote, R. Schilder, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

C. Sessa, N. Colombo, C. Fotopoulou, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy.

F. Veglia, C. Cipolla, C. Fiorentini, 2010, Journal of the American College of Cardiology.

Prevention of Atrial Fibrillation in High-risk Patients Undergoing Lung Cancer Surgery: The PRESAGE Trial

M. Casiraghi, M. Venturino, L. Spaggiari, 2016, Annals of surgery.